• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Johns Hopkins Rheumatology

Show Search
Hide Search
  • About Us
    • Our History
    • Our Faculty
    • Rheumatology Fellowship
    • Administrative Core
    • Contact Us
    • eNews Signup
  • Make an Appointment
    • Clinic Information
    • Specialty Clinics
  • Our Research
    • Current Research Studies
    • Andrade Lab
    • Darrah Lab
    • Konig Lab
    • Rosen Casciola Lab
    • RDRCC
    • Bayview Immunomics Core (BIC)
  • Charitable Giving
    • Dr. John Welton Fellowship in Rheumatology
    • Dr. Ira T. Fine Discovery Fund
    • Dr. Nadia D. Morgan Memorial Fund
  • News
    • LEAP Magazine
  • Education
    • Advances in the Diagnosis and Treatment of the Rheumatic Diseases Course
    • RheumTV – Patient Education Video Library
Home / News / Research / Muscle biopsy findings identify a unique subgroup of patients with severe Scleroderma

Muscle biopsy findings identify a unique subgroup of patients with severe Scleroderma

August 1, 2017 By Erika Darrah

Summary

People with the scleroderma experience a thickening of the skin and other tissues in the body. A study from the Division of Rheumatology led by Julie J. Paik MD, MHS, Laura K. Hummers MD, ScM, and Andrew L. Mammen, MD, PhD found that some patients experience muscle weakness due to an accumulation of fibrous tissue in their muscles without signs of inflammation, called “fibrosing myopathy”. Fibrosing myopathy was associated with a worse clinical outcome including increased death from cardiac disease, stressing the need to further monitor scleroderma patients with this finding.

Why was this study done?

Although it was known that a large portion of people with scleroderma experience muscle weakness, the causes of weakness and associated long term outcomes have not been completely studied. For this study, the researchers wanted to determine if unique subtypes of scleroderma muscle disease existed among different patients. They also wanted to understand if this information, obtained through a muscle biopsy, was associated with other physical features of the disease, laboratory findings, and long-term outcomes.

How was this study done?

This study was completed by reviewing medical charts, laboratory data, blood specimens, and muscle biopsies from over 1500 patients seen at the Johns Hopkins Scleroderma Center between 1990 and 2014. Almost 25% of patients seen by the center during this period experienced muscle weakness. From this group, the researchers studied muscle biopsies from 37 people with scleroderma who had obvious signs of muscle weakness. Eight people whose biopsies showed an accumulation of fibrous tissue in the muscle without inflammation were considered to have “fibrosing myopathy”. Muscle biopsies from the other 29 peopled showed signs of inflammation so were considered to have “inflammatory myopathy”. Data including physical features of scleroderma, laboratory findings, and long-term survival were compared between these two distinct groups of patients.

What were the major findings?

People with scleroderma who had fibrosing myopathy were more likely to have widespread thickening of the skin over many areas of the body, be of African-American race, and have lower “forced vital capacity” (indicating impaired lung function), compared to people with inflammatory myopathy. They also had lower levels of muscle enzymes, indicating less ongoing damage to the muscle. However, people with fibrosing myopathy had a significantly higher mortality (5 of 8 with fibrosing myopathy; 62.5% compared to 4 of 29 with inflammatory myopathy (14.3%). The cause of death in 60% of these patients was due to cardiac disease.

What is the impact of this work?

Fibrosing myopathy is a unique subtype of muscle disease that can be observed in people with scleroderma. It is associated with a higher risk of mortality, especially due to cardiac disease. This underscores the importance of learning more about this unique muscle finding to identify how best to monitor and treat this group of scleroderma patients at risk for severe disease outcomes.

This research was supported by:

The Johns Hopkins Rheumatic Disease Research Core Center, Donald B. and Dorothy L. Stabler Foundation, Doris Duke Early Clinician Investigator Award, John Staurulakis Endowed Scholar Award, Chresanthe Stauralakis Memorial Discovery Fund, Scleroderma Research Foundation and McCrory Professorship, and in part, by the Intramural Research Program of the National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health (K23 AR-061439, P30-AR053503).

Link to original research article:

Fibrosing myopathy in systemic sclerosis associates with higher mortality. Paik JJ, Wigley FM, Shah AA, Corse AM, Casciola-Rosen L, Hummers LK, Mammen AL. Arthritis Care Res (Hoboken). 2017 May 23. doi: 10.1002/acr.23291. [Epub ahead of print]

Receive the Latest News from Johns Hopkins Rheumatology

Receive the Latest News from Johns Hopkins Rheumatology

Join our mailing list to receive the latest news and updates from Johns Hopkins Rheumatology.

Interested In

You have Successfully Subscribed!

Filed Under: Research Tagged With: Fibrosing Myopapthy, Scleroderma

Erika Darrah

Erika Darrah, Ph.D. is an Assistant Professor of Medicine in the Johns Hopkins University Division of Rheumatology with an interest understanding the mechanisms that drive the development of rheumatic diseases.

Use of this Site

All information contained within the Johns Hopkins Division of Rheumatology website is intended for educational purposes only. Physicians and other health care professionals are encouraged to consult other sources and confirm the information contained within this site. Consumers should never disregard medical advice or delay in seeking it because of something they may have read on this website.

Primary Sidebar

Rheumatology News

  • News
  • Promotions

Recent News

LEAP – Winter 2023: Big Data, Individualized Care

February 23, 2023

LEAP Rounds – Holiday 2022

November 9, 2022

Dr. Rachel Wallwork named ACR Distinguished Fellow

October 19, 2022

RheumTV Logo

Rheum.TV is an educational platform created to help patients living with a rheumatic disease. With over 100 disease education videos produced by the team at Johns Hopkins Rheumatology.

Visit RheumTV

Footer

Rheumatology Specialty Care Centers

  • Johns Hopkins Arthritis Center
  • Johns Hopkins Lupus Center
  • Johns Hopkins Lyme Disease Research Center
  • Johns Hopkins Myositis Center
  • Johns Hopkins Scleroderma Center
  • Johns Hopkins Sjögren’s Syndrome Center
  • Johns Hopkins Vasculitis Center

Connect with Us

  • Facebook
  • Twitter
  • YouTube
U.S. News and World Report Rankings Badge

Johns Hopkins Medicine

© 2023 Johns Hopkins Rheumatology - Patient Privacy